Despite the fact that the loss of SMARCA4 was associated with an unfavorable prognosis, it has been suggested as a novel prognostic biomarker for predicting outcomes in NSCLC cases on platinum-based chemotherapy after tumor resection, with improved five-year disease-specific survival noted in patients with low SMARCA4 expression [27]. Here, SMARCA4 is linked to neoplasm.